Navigation Links
Valeant to Acquire Polish Products
Date:10/30/2009

ALISO VIEJO, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today announced that it has agreed to acquire the rights to several prescription and cosmetic dermatology products from a privately-held, Polish specialty pharmaceutical company. The products have approximately $8 million in annual sales and Valeant will acquire the rights to all products for approximately $18 million. A portion of the purchase price was paid upon signing and the remaining balance will be paid upon closing. The transaction is expected to close in the first quarter of 2010 and will be accretive to Valeant in 2010.

"We continue to focus our development efforts in building leading dermatology franchises in each of our select regions," stated J. Michael Pearson, chairman and chief executive officer. "This latest transaction adds new complementary prescription and cosmetic products to our current portfolio in Central Europe and fits in well with our existing infrastructure. In addition, the dermatology products will increase our visibility with the dermatologists in these markets."

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding the consummation of the acquisition, the potential for Valeant to build its regional franchises and the impact of the acquisition on Valeant's results of operation. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the U.S. Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)

    Contact:
    Laurie W. Little
    Valeant Pharmaceuticals
    949-461-6002
    laurie.little@valeant.com

SOURCE Valeant Pharmaceuticals International


'/>"/>
SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou
2. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
3. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
4. BioMarin Acquires Huxley Pharmaceuticals, Inc.
5. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
6. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
7. BD Announces Agreement to Acquire HandyLab, Inc.
8. Seguro Acquires Worldwide Rights to Johns Hopkins Abdominal Surgery Device
9. Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University
10. Onyx Pharmaceuticals to Acquire Proteolix, Inc.
11. ResMed Acquires Laboratoires Narval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
(Date:4/19/2017)... , April 19, 2017  Vanderbilt University Medical Center ... in Nashville , Tennesse have been ... Sphincter Stimulation for GERD (LESS GERD) trial. The EndoStim ... long-term reflux control by restoring normal function to the ... million people in the United States ...
(Date:4/19/2017)... Companion animal vaccines ... pets such as canine, avian and feline. ... such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated ... Recombinant Vaccines. Attenuated live vaccines are derived from ... have been weakend under laboratory conditions. Conjugate vaccines ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... The John P. McGovern Museum of Health ... anywhere to track their cognitive health, and share results with their physicians. Members and ... on the museum's website. , BrainCheck founder, Dr. David Eagleman, formerly at Baylor College ...
(Date:4/24/2017)... Ill., and Waycross, Ga. (PRWEB) , ... April ... ... market leader and trusted advisor within the telehealth industry, announces the company’s VideoMedicine ... U.S. board-certified primary care providers. Available 24 hours a day, Quick Care provides ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... designed to recognize elevated anxiety levels in people with addiction who are served ... Smart Patch, a biosensing wearable device that monitors heart and breath rates to ...
(Date:4/24/2017)... ... April 24, 2017 , ... Come to PAINWeekEnd (PWE) Tampa ... Walter Blvd, for an educational and exciting 2-day program. , An attendee at ... this before they approach patients” about the course entitled Ain't Misbehavin': Decreasing and Managing ...
(Date:4/24/2017)... ... ... “Reflections of God’s Work”: an enlightening collection of life lessons leading each ... published author, Jerri Broglin, a survivor of great loss who gained insight on how ... for those searching for answers, as we are finding the answers that are so ...
Breaking Medicine News(10 mins):